Telomerase activation: one step on the road to cancer?

[1]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[2]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[3]  M. Blasco,et al.  Expression of mouse telomerase catalytic subunit in embryos and adult tissues. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Ciechanover,et al.  Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Hannon,et al.  Myc activates telomerase. , 1998, Genes & development.

[6]  R. Pollock,et al.  Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Robert A. Weinberg,et al.  Expression of TERT in early premalignant lesions and a subset of cells in normal tissues , 1998, Nature Genetics.

[8]  R. Lance,et al.  The association between telomerase, p53, and clinical staging in colorectal cancer. , 1998, American journal of surgery.

[9]  V. Lundblad,et al.  The telomerase reverse transcriptase: components and regulation. , 1998, Genes & development.

[10]  L. Chin,et al.  Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation , 1998, Oncogene.

[11]  J. Kigawa,et al.  Alteration of Telomerase Activity Associated With Development and Extension of Epithelial Ovarian Cancer , 1998, Obstetrics and gynecology.

[12]  S. Benchimol,et al.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span , 1998, Current Biology.

[13]  Bas van Steensel,et al.  TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.

[14]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[15]  T. Lange.  Telomeres and Senescence: Ending the Debate , 1998 .

[16]  C. Greider.  Telomerase activity, cell proliferation, and cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Takahashi,et al.  Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. , 1997, Biochemical and biophysical research communications.

[18]  María A Blasco,et al.  Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.

[19]  R. Weinberg,et al.  hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization , 1997, Cell.

[20]  H. Shirasawa,et al.  Transactivation of Prothymosin α and c-mycPromoters by Human Papillomavirus Type 16 E6 Protein , 1997 .

[21]  R. Schlegel,et al.  The Human Papillomavirus Type 16 E6 and E7 Oncoproteins Dissociate Cellular Telomerase Activity from the Maintenance of Telomere Length* , 1997, The Journal of Biological Chemistry.

[22]  R. Eisenman,et al.  Myc target genes. , 1997, Trends in biochemical sciences.

[23]  T R Hughes,et al.  Reverse transcriptase motifs in the catalytic subunit of telomerase. , 1997, Science.

[24]  Bas van Steensel,et al.  Control of telomere length by the human telomeric protein TRF1 , 1997, Nature.

[25]  A. Takashima,et al.  Mechanisms regulating telomerase activity in murine T cells. , 1997, Journal of immunology.

[26]  H. Mizoguchi,et al.  Up-regulation of telomerase activity in human lymphocytes. , 1996, Biochimica et biophysica acta.

[27]  D. Galloway,et al.  The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. , 1996, Seminars in cancer biology.

[28]  D. Hanahan,et al.  Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. , 1996, The American journal of pathology.

[29]  J. Huibregtse,et al.  Mechanism of HPV E6 proteins in cellular transformation. , 1996, Seminars in cancer biology.

[30]  C. Autexier,et al.  Telomerase and cancer: revisiting the telomere hypothesis. , 1996, Trends in biochemical sciences.

[31]  C. Greider,et al.  Telomerase regulation during entry into the cell cycle in normal human T cells. , 1996, Molecular biology of the cell.

[32]  H. Varmus,et al.  Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation , 1996, Molecular and cellular biology.

[33]  G. Roos,et al.  Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas , 1996 .

[34]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[35]  H. Igarashi,et al.  Telomerase activity is induced by the stimulation to antigen receptor in human peripheral lymphocytes. , 1996, Biochemical and biophysical research communications.

[36]  D. Hanahan,et al.  Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis , 1996, Nature Genetics.

[37]  D. Hanahan,et al.  Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. , 1995, Oncogene.

[38]  Jonathan A. Cooper,et al.  Beating a path to Myc , 1995, Nature.

[39]  J. Shay,et al.  Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. , 1995, Journal of immunology.

[40]  T. Slaga,et al.  Increased telomerase activity in mouse skin premalignant progression. , 1995, Cancer research.

[41]  E. Musgrove,et al.  Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. , 1995, Oncogene.

[42]  R. DePinho,et al.  Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[44]  P. Auewarakul,et al.  Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors , 1994, Molecular and cellular biology.

[45]  D. Galloway,et al.  The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. , 1994, Virology.

[46]  D. Hanahan,et al.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.

[47]  H. Pan,et al.  Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. , 1994, Genes & development.

[48]  M. Kulesz-Martin,et al.  Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis. , 1994, Cancer research.

[49]  S. Barber,et al.  Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells , 1994, Molecular and cellular biology.

[50]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[51]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[52]  H. Hausen.  Viruses in human cancers , 1991 .

[53]  P. Howley,et al.  Role of the human papillomaviruses in human cancer. , 1991, Cancer research.

[54]  R. Schlegel,et al.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes , 1989, Journal of virology.

[55]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[56]  P. Nowell,et al.  Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Ohlsson,et al.  Spatial and temporal pattern of cellular myc oncogene expression in developing human placenta: Implications for embryonic cell proliferation , 1984, Cell.

[58]  P. Leder,et al.  Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. , 1984, Science.

[59]  R. Palmiter,et al.  Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors , 1984, Cell.

[60]  R. Weinberg,et al.  Cellular oncogenes and multistep carcinogenesis. , 1983, Science.

[61]  H. Varmus,et al.  Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas , 1982, Nature.

[62]  G. Roos,et al.  Telomere shortening in renal cell carcinoma. , 1994, Cancer research.

[63]  C. Harley,et al.  Telomerase, cell immortality, and cancer. , 1994, Cold Spring Harbor symposia on quantitative biology.

[64]  J. Shay,et al.  E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. , 1993, Oncogene.

[65]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[66]  G. Crabtree,et al.  Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. , 1990, Annual review of immunology.

[67]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[68]  T. Slaga,et al.  Studies on the Mechanisms Involved in Multistage Carcinogenesis in Mouse Skin , 1982, Journal of cellular biochemistry.